{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:37:29Z","timestamp":1793716649065,"version":"4.6.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001713","name":"EDCTP","doi-asserted-by":"crossref","award":["RIA2017T-2019"],"award-info":[{"award-number":["RIA2017T-2019"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Tuberculous meningitis (TBM) is the most lethal and disabling form of tuberculosis (TB), particularly in sub-Saharan Africa. Current anti-TB treatment is poorly effective since TBM mortality reaches 40% in HIV-negative patients and up to 70% in HIV-co-infected patients. To reduce TBM-induced morbidity and mortality, the INTENSE-TBM trial evaluates two interventions in both HIV-infected and uninfected patients: an anti-TB treatment intensification using oral high-dose rifampicin (35 mg\/kg daily) and linezolid (1200 mg daily and then 600 mg daily) during the first 8 weeks of the anti-TB treatment and the use of adjunctive aspirin (200 mg daily).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a randomized controlled, phase III, multicenter, 2 \u00d7 2 factorial plan superiority trial. The trial has four arms, combining the two experimental treatments (intensified TBM regimen and aspirin) with the two reference treatments (WHO standard TB treatment and placebo), and is open-label for anti-TB treatment and double-blind placebo-controlled for aspirin treatment. This trial is conducted in adults or adolescents of age \u226515 years with TBM defined as \u201cdefinite,\u201d \u201cprobable,\u201d or \u201cpossible\u201d using Tuberculosis Meningitis International Research Consortium criteria, in four African countries: Ivory Coast, Madagascar, Uganda, and South Africa. The primary outcome is all-cause death between inclusion and week 40.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The INTENSE-TBM trial represents a key opportunity to enhance TBM treatment with widely available existing drugs notably in high-incidence settings of both TB and HIV. The trial design is pragmatic and the results will permit early and effective applications in TBM patient care, in both HIV and TB high-incidence countries.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov NCT04145258. Registered on October 30, 2019.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-06772-1","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T06:02:36Z","timestamp":1667887356000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Intensified tuberculosis treatment to reduce the mortality of HIV-infected and uninfected patients with tuberculosis meningitis (INTENSE-TBM): study protocol for a phase III randomized controlled trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Thomas","family":"Maitre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryline","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Calmy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaja","family":"Raberahona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rivonirina Andry","family":"Rakotoarivelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niaina","family":"Rakotosamimanana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ambrosioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Mir\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Debeaudrap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad","family":"Muzoora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angharad","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Meintjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Wasserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Eholi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric Ello","family":"Nogbou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Camilla","family":"Calvo-Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corine","family":"Chazallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Machault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Anglaret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5927-4178","authenticated-orcid":false,"given":"Fabrice","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"key":"6772_CR1","unstructured":"World Health Organization. Global tuberculosis report 2021.\u00a02021.\u00a0https:\/\/www.who.int\/tb\/publications\/global_report\/en\/."},{"key":"6772_CR2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nrneurol.2017.120","volume":"13","author":"RJ Wilkinson","year":"2017","unstructured":"Wilkinson RJ, Rohlwink U, Misra UK, van Crevel R, Mai NTH, Dooley KE, et al. Tuberculous meningitis. Nat Rev Neurol. 2017;13:581\u201398.","journal-title":"Nat Rev Neurol"},{"key":"6772_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2334-14-9","volume":"14","author":"T Gomes","year":"2014","unstructured":"Gomes T, Reis-Santos B, Bertolde A, Johnson JL, Riley LW, Maciel EL. Epidemiology of extrapulmonary tuberculosis in Brazil: a hierarchical model. BMC Infect Dis. 2014;14:9.","journal-title":"BMC Infect Dis"},{"key":"6772_CR4","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/S1473-3099(19)30066-0","volume":"19","author":"MW Tenforde","year":"2019","unstructured":"Tenforde MW, Mokomane M, Leeme TB, Tlhako N, Tsholo K, Chebani T, et al. Mortality in adult patients with culture-positive and culture-negative meningitis in the Botswana national meningitis survey: a prevalent cohort study. Lancet Infect Dis. 2019;19:740\u20139.","journal-title":"Lancet Infect Dis"},{"key":"6772_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(16)30274-2","volume":"17","author":"MJ Boeree","year":"2017","unstructured":"Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2017;17:39\u201349.","journal-title":"Lancet Infect Dis"},{"key":"6772_CR6","doi-asserted-by":"publisher","first-page":"e01054","DOI":"10.1128\/AAC.01054-17","volume":"61","author":"RE Aarnoutse","year":"2017","unstructured":"Aarnoutse RE, Kibiki GS, Reither K, Semvua HH, Haraka F, Mtabho CM, et al. Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis. Antimicrob Agents Chemother. 2017;61:e01054\u201317.","journal-title":"Antimicrob Agents Chemother"},{"key":"6772_CR7","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1164\/rccm.201407-1264OC","volume":"191","author":"MJ Boeree","year":"2015","unstructured":"Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med. 2015;191:1058\u201365.","journal-title":"Am J Respir Crit Care Med"},{"key":"6772_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1056\/NEJMe1511990","volume":"374","author":"PR Donald","year":"2016","unstructured":"Donald PR. Chemotherapy for Tuberculous Meningitis. N Engl J Med. 2016;374:179\u201381.","journal-title":"N Engl J Med"},{"key":"6772_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1473-3099(12)70264-5","volume":"13","author":"R Ruslami","year":"2013","unstructured":"Ruslami R, Ganiem AR, Dian S, Apriani L, Achmad TH, van der Ven AJ, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis. 2013;13:27\u201335.","journal-title":"Lancet Infect Dis"},{"key":"6772_CR10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1056\/NEJMoa1507062","volume":"374","author":"AD Heemskerk","year":"2016","unstructured":"Heemskerk AD, Bang ND, Mai NTH, Chau TTH, Phu NH, Loc PP, et al. Intensified Antituberculosis Therapy in Adults with Tuberculous Meningitis. N Engl J Med. 2016;374:124\u201334.","journal-title":"N Engl J Med"},{"key":"6772_CR11","doi-asserted-by":"publisher","first-page":"e01014","DOI":"10.1128\/AAC.01014-18","volume":"62","author":"S Dian","year":"2018","unstructured":"Dian S, Yunivita V, Ganiem AR, Pramaesya T, Chaidir L, Wahyudi K, et al. Double-Blind, Randomized, Placebo-Controlled Phase II Dose-Finding Study To Evaluate High-Dose Rifampin for Tuberculous Meningitis. Antimicrob Agents Chemother. 2018;62:e01014\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"6772_CR12","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1164\/rccm.200806-892OC","volume":"178","author":"R Dietze","year":"2008","unstructured":"Dietze R, Hadad DJ, McGee B, Molino LPD, Maciel ELN, Peloquin CA, et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med. 2008;178:1180\u20135.","journal-title":"Am J Respir Crit Care Med"},{"key":"6772_CR13","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","volume":"367","author":"M Lee","year":"2012","unstructured":"Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med. 2012;367:1508\u201318.","journal-title":"N Engl J Med"},{"key":"6772_CR14","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1128\/CMR.00007-10","volume":"23","author":"R Nau","year":"2010","unstructured":"Nau R, S\u00f6rgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010;23:858\u201383.","journal-title":"Clin Microbiol Rev"},{"key":"6772_CR15","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1097\/INF.0b013e3181df4b9a","volume":"29","author":"R Yogev","year":"2010","unstructured":"Yogev R, Damle B, Levy G, Nachman S. Pharmacokinetics and distribution of linezolid in cerebrospinal fluid in children and adolescents. Pediatr Infect Dis J. 2010;29:827\u201330.","journal-title":"Pediatr Infect Dis J"},{"key":"6772_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40780-018-0123-1","volume":"4","author":"S Hashimoto","year":"2018","unstructured":"Hashimoto S, Honda K, Fujita K, Miyachi Y, Isoda K, Misaka K, et al. Effect of coadministration of rifampicin on the pharmacokinetics of linezolid: clinical and animal studies. J Pharm Health Care Sci. 2018;4:27.","journal-title":"J Pharm Health Care Sci"},{"key":"6772_CR17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/0091270010366445","volume":"51","author":"K Gandelman","year":"2011","unstructured":"Gandelman K, Zhu T, Fahmi OA, Glue P, Lian K, Obach RS, et al. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J Clin Pharmacol. 2011;51:229\u201336.","journal-title":"J Clin Pharmacol"},{"key":"6772_CR18","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1093\/jac\/dks153","volume":"67","author":"F Pea","year":"2012","unstructured":"Pea F, Viale P, Cojutti P, Del Pin B, Zamparini E, Furlanut M. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother. 2012;67:2034\u201342.","journal-title":"J Antimicrob Chemother"},{"key":"6772_CR19","doi-asserted-by":"publisher","first-page":"e02164","DOI":"10.1128\/AAC.02164-18","volume":"63","author":"S Wasserman","year":"2019","unstructured":"Wasserman S, Denti P, Brust JCM, Tareq M, Hlungulu S, Wiesner L, et al. Linezolid pharmacokinetics in South African patients with drug resistant tuberculosis and a high prevalence of HIV co-infection. Antimicrob Agents Chemother. 2019;63:e02164\u201318.","journal-title":"Antimicrob Agents Chemother"},{"key":"6772_CR20","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1183\/09031936.00195210","volume":"38","author":"M Villar","year":"2011","unstructured":"Villar M, Sotgiu G, D\u2019Ambrosio L, Raymundo E, Fernandes L, Barbedo J, et al. Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis. Eur Respir J. 2011;38:730\u20133.","journal-title":"Eur Respir J"},{"key":"6772_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jns.2010.12.015","volume":"303","author":"UK Misra","year":"2011","unstructured":"Misra UK, Kalita J, Maurya PK. Stroke in tuberculous meningitis. J Neurol Sci. 2011;303:22\u201330.","journal-title":"J Neurol Sci"},{"key":"6772_CR22","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1056\/NEJMoa040573","volume":"351","author":"GE Thwaites","year":"2004","unstructured":"Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TTO, Nguyen TCT, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004;351:1741\u201351.","journal-title":"N Engl J Med"},{"key":"6772_CR23","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/newbio231232a0","volume":"231","author":"JR Vane","year":"1971","unstructured":"Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231:232\u20135.","journal-title":"Nat New Biol"},{"key":"6772_CR24","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.33478","volume":"7","author":"NT Mai","year":"2018","unstructured":"Mai NT, Dobbs N, Phu NH, Colas RA, Thao LT, Thuong NT, et al. A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults. eLife. 2018;7:e33478.","journal-title":"eLife."},{"key":"6772_CR25","unstructured":"World Health Organization. consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection.\u00a02016.\u00a0https:\/\/www.int\/hiv\/pub\/arv\/arv-2016\/en\/."},{"key":"6772_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162775","volume":"11","author":"GW Rutherford","year":"2016","unstructured":"Rutherford GW, Horvath H. Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review. PLoS One. 2016;11:e0162775.","journal-title":"PLoS One"},{"key":"6772_CR27","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/cid\/cix305","volume":"64","author":"BJ Marais","year":"2017","unstructured":"Marais BJ, Heemskerk AD, Marais SS, van Crevel R, Rohlwink U, Caws M, et al. Standardized Methods for Enhanced Quality and Comparability of Tuberculous Meningitis Studies. Clin Infect Dis. 2017;64:501\u20139.","journal-title":"Clin Infect Dis"},{"key":"6772_CR28","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ijantimicag.2016.06.016","volume":"48","author":"V Yunivita","year":"2016","unstructured":"Yunivita V, Dian S, Ganiem AR, Hayati E, Hanggono Achmad T, Purnama Dewi A, et al. Pharmacokinetics and safety\/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients. Int J Antimicrob Agents. 2016;48:415\u201321.","journal-title":"Int J Antimicrob Agents"},{"key":"6772_CR29","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00140-21","volume":"65","author":"S Wasserman","year":"2021","unstructured":"Wasserman S, Davis A, Stek C, Chirehwa M, Botha S, Daroowala R, et al. Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial. Antimicrob Agents Chemother. 2021;65:e0014021.","journal-title":"Antimicrob Agents Chemother"},{"key":"6772_CR30","unstructured":"World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. [Internet]. 2017. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK475977\/. [Cited 2021 Jan 11]."},{"key":"6772_CR31","unstructured":"World Health Organization, Special Programme for Research and Training in Tropical Diseases. Good clinical laboratory practice (GCLP). [Internet]. Geneva, Switzerland: World Health Organization; 2009. Available from: http:\/\/apps.who.int\/tdr\/svc\/publications\/tdr-research-publications\/gclp-web. [Cited 2020 Nov 30]."},{"key":"6772_CR32","unstructured":"Clinical Trial Management Adaptation to ICH E6 (R2): Good Clinical Practice [Internet]. ISPE | International Society for Pharmaceutical Engineering. Available from: https:\/\/ispe.org\/pharmaceutical-engineering\/january-february-2019\/clinical-trial-management-adaptation-ich-e6-r2. [Cited 2020 Nov 30]."},{"key":"6772_CR33","doi-asserted-by":"publisher","unstructured":"Ariza-Vioque E, Ello F, Andriamamonjisoa H, Machault V, Gonz\u00e1lez-Mart\u00edn J, Calvo-Cort\u00e9s MC, et al. Capacity Building in Sub-Saharan Africa as Part of the INTENSE-TBM Project During the COVID-19 Pandemic. Infect Dis Ther. 2022:1\u201315. https:\/\/doi.org\/10.1007\/s40121-022-00667-z.","DOI":"10.1007\/s40121-022-00667-z"},{"key":"6772_CR34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.12688\/wellcomeopenres.14691.1","volume":"3","author":"FV Cresswell","year":"2018","unstructured":"Cresswell FV, Ssebambulidde K, Grint D, Te Brake L, Musabire A, Atherton RR, et al. High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study). Wellcome Open Res. 2018;3:83.","journal-title":"Wellcome Open Res"},{"key":"6772_CR35","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1093\/cid\/ciz1071","volume":"71","author":"EM Svensson","year":"2020","unstructured":"Svensson EM, Dian S, Te Brake L, Ganiem AR, Yunivita V, van Laarhoven A, et al. Model-Based Meta-analysis of Rifampicin Exposure and Mortality in Indonesian Tuberculous Meningitis Trials. Clin Infect Dis. 2020;71:1817\u201323.","journal-title":"Clin Infect Dis"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06772-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06772-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06772-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T06:08:10Z","timestamp":1667887690000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06772-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,8]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6772"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06772-1","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,8]]},"assertion":[{"value":"16 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial received ethical approval from CNESVS (Comit\u00e9 National d'Ethique des Sciences de la Vie et de la Sant\u00e9, C\u00f4te d'Ivoire), Comit\u00e9 d\u00b4Ethique de la Recherche Biom\u00e9dicale, Madagascar), UNCST (Uganda National Council for Science & Technology, Uganda), University of Cap Town HREC (Human Research Ethics Committee, South Africa). Participants must provide signed and dated written informed consent prior to undergoing any study-specific procedure. For the patient with a Glasgow Coma Scale <15, the consent of a relative or a study-independent doctor is required. Deferred consent is to be obtained from the participant when their level of consciousness improves and they have the capacity to provide consent. For adolescent below the age of civil, the consent of at least one parent or legal guardian and the consent or assent of the adolescent is required","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J.M. Miro has received consulting honoraria and\/or research grants from AbbVie, Angelini, Contrafect, Genentech, Gilead Sciences, Jansen, Lysovant, Medtronic, MSD, Novartis, Pfizer, and ViiV Healthcare, outside the submitted work.  F. Bonnet has received consulting honoraria and\/or research grants from Gilead Sciences, Jansen, MSD, and ViiV Healthcare, outside the submitted work.\u00a0The other authors have any competing interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"928"}}